COST-EFFECTIVENESS OF RESPIRATORY SYNCYTIAL VIRUS PROPHYLAXIS WITH PALIVIZUMAB AMONG PRETERM INFANTS COVERED BY MEDICAID IN THE UNITED STATES

被引：1
|
作者：
Weiner, L. B. [1 ]
Polak, M. J. [2 ]
Masaquel, A. [3 ]
Mahadevia, P. J. [3 ]
机构：
[1] Upstate Med Univ, Syracuse, NY USA
[2] W Virginia Univ, Sch Med, Morgantown, WV 26506 USA
[3] MedImmune, Gaithersburg, MD USA
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 03期
关键词：
D O I：
10.1016/j.jval.2011.02.655
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A118 / A118
页数：1
相关论文
共 50 条
  • [41] Respiratory illness and respiratory syncytial virus hospitalization in infants with a tracheostomy following prophylaxis with palivizumab
    Bosco Paes
    Mahwesh Saleem
    Doyoung Kim
    Krista L. Lanctôt
    Ian Mitchell
    European Journal of Clinical Microbiology & Infectious Diseases, 2019, 38 : 1561 - 1568
  • [42] Comparison of the Cost of Hospitalization for Respiratory Syncytial Virus Disease Versus Palivizumab Prophylaxis in Canadian Inuit Infants
    Banerji, Anna
    Lanctot, Krista L.
    Paes, Bosco A.
    Masoud, Shababa T.
    Tam, Derrick Y.
    Macdonald, W. Alexander
    Roberts, Ann
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2009, 28 (08) : 702 - 706
  • [43] Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain
    Sanchez-Luna, M.
    Burgos-Pol, R.
    Oyaguez, I.
    Figueras-Aloy, J.
    Sanchez-Solis, M.
    Martinon-Torres, F.
    Carbonell-Estrany, X.
    BMC INFECTIOUS DISEASES, 2017, 17
  • [44] Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain
    M. Sanchez-Luna
    R. Burgos-Pol
    I. Oyagüez
    J. Figueras-Aloy
    M. Sánchez-Solís
    F. Martinón-Torres
    X. Carbonell-Estrany
    BMC Infectious Diseases, 17
  • [45] Respiratory illness and respiratory syncytial virus hospitalization in infants with a tracheostomy following prophylaxis with palivizumab
    Paes, Bosco
    Saleem, Mahwesh
    Kim, Doyoung
    Lanctot, Krista L.
    Mitchell, Ian
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2019, 38 (08) : 1561 - 1568
  • [46] Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia
    Ordonez, Jaime E.
    Huertas, Victor M.
    BMC INFECTIOUS DISEASES, 2024, 24 (01)
  • [47] Effectiveness of palivizumab immunoprophylaxis in infants with respiratory syncytial virus disease in Colombia
    Gabriel Pineros, Juan
    De la Hoz-Valle, Jose
    Galvis, Clara
    Celis, Astrid
    Ovalle, Oscar
    Cecilia Sandoval, Carmen
    Orrego, Jaime
    Vides, Saby
    Rojas, Iader
    Bustamante, Hernando
    Gallon, Carlos
    Alberto Mesa, Jaime
    JOURNAL OF INFECTION IN DEVELOPING COUNTRIES, 2021, 15 (11): : 1708 - 1713
  • [48] Effect of Palivizumab Prophylaxis on Respiratory Syncytial Virus Infection in Very Preterm Infants in the First Year of Life in The Netherlands
    Schepp, Rutger M.
    Kaczorowska, Joanna
    van Gageldonk, Pieter G. M.
    Rouers, Elsbeth D. M.
    Sanders, Elisabeth A. M.
    Bruijning-Verhagen, Patricia C. J.
    Berbers, Guy A. M.
    VACCINES, 2023, 11 (12)
  • [49] Utilization Management Opportunities for Palivizumab for Prophylaxis of Respiratory Syncytial Virus Complications in Infants
    Curtiss, Frederic R.
    Fairman, Kathleen A.
    JOURNAL OF MANAGED CARE PHARMACY, 2010, 16 (01): : 59 - 66
  • [50] Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants
    Pedraz, C
    Carbonell-Estrany, X
    Figueras-Aloy, J
    Quero, J
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2003, 22 (09) : 823 - 827
12345